Commissioner of Income-tax v Shasun Chemicals & Drugs Limited is an important judgment delivered by the Madras High Court on April 25, 2011, establishing the eligibility of share issue expenses for amortization under Section 35D of the Income Tax Act, 1961. The High Court affirmed that expenditures incurred by an Indian company in connection with the issue of shares for the expansion of an existing industrial undertaking or setting up a new industrial unit qualify for amortized deduction in equal installments over ten successive assessment years.
Corporate Background and Procedural History
The assessee, Shasun Chemicals & Drugs Limited, is an Indian public limited company engaged in the manufacture and export of active pharmaceutical ingredients and bulk drugs. In previous assessment years, the company incurred substantial expenditure on public and rights share issues to fund the expansion of its manufacturing facilities and industrial undertakings. The assessee claimed one-tenth of these share issue expenses as an amortized deduction under Section 35D for the assessment years 1999-2000 and 2001-02.
The Assessing Officer disallowed the amortized deduction, relying on the Supreme Court ruling in Brooke Bond India Ltd v CIT, which held that share issue expenditure is capital in nature and not deductible as general business expenditure under Section 37. The Commissioner of Income-Tax (Appeals) and the Income Tax Appellate Tribunal (ITAT) Madras 'C' Bench reversed the disallowance, holding that Section 35D is a specific statutory code that expressly allows amortization of capital share issue costs incurred for industrial expansion. The Revenue appealed to the Madras High Court under Section 260A.
Statutory Provisions and Questions of Law
The appeal required the High Court to examine whether the statutory amortization benefit under Section 35D overrides the general common law prohibition against capital expenditure deductions. The primary statutory provisions considered were:
- Section 35D of the Income Tax Act: Allows an Indian company to amortize specified preliminary expenses incurred before the commencement of business or in connection with the extension of an industrial undertaking or setting up a new industrial unit.
- Section 35D(2)(c)(iv) of the Income Tax Act: Explicitly includes expenditure incurred in connection with the issue of shares or debentures, including underwriting commission, brokerage, and printing costs.
- Section 37(1) of the Income Tax Act: General residual deduction provision for revenue expenditure laid out wholly and exclusively for business purposes.
- Principle of Consistency in Tax Assessment: Rule prohibiting the Revenue from arbitrarily disallowing recurring amortized claims in subsequent years when the initial claim was examined and accepted in earlier years.
The substantial question of law framed was whether the tribunal was legally correct in holding that expenditure incurred on the issue of shares is eligible to be amortized under Section 35D of the Income Tax Act.
High Court Analysis and Judicial Findings
The Madras High Court held that the reliance placed by the Revenue on general decisions governing Section 37 was misplaced. The Supreme Court ruling in Brooke Bond India Ltd established that capital expenditure cannot be claimed as a revenue deduction under Section 37(1). However, Parliament subsequently enacted Section 35D to provide a specific, structured incentive allowing corporate entities to write off specified capital expenditures across a ten-year timeline.
The bench observed that Section 35D(2)(c)(iv) expressly mentions expenditure in connection with the issue of shares to the public for subscription, including underwriting commission, drafting, typing, and printing of prospectuses. As long as the company satisfies the statutory condition that the share issue was conducted for the extension of an industrial undertaking or the creation of a new industrial unit, the amortized deduction cannot be denied.
Furthermore, the court emphasized the rule of consistency in tax administration. Where the original claim under Section 35D was verified and accepted by the Assessing Officer in the initial year of expenditure, the Revenue cannot abruptly disallow the subsequent annual installments without demonstrating fresh material or changed statutory circumstances.
Significance for Corporate Finance and Capital Raising
The Shasun Chemicals judgment provides vital clarity for corporate entities raising equity capital in India:
- Statutory Shield for Equity Expansion: Expenses associated with the allotment of shares, initial public offerings (IPOs), and rights issues are legally amortizable under Section 35D when linked to industrial growth.
- Documenting Capital Utilization: Companies must maintain clear project reports and accounting trails proving that equity proceeds were utilized for expanding manufacturing units or establishing new industrial facilities.
- Consistency in Multiannual Deductions: Once an amortized deduction is accepted in year one, taxpayers have strong judicial backing to claim the remaining installments across subsequent years.
- Strategic Advisory Support: Leveraging professional virtual CFO services helps expanding companies structure share issues efficiently while optimizing direct tax deductions.
The decision continues to serve as an authoritative precedent safeguarding legitimate tax incentives for capital formation and industrial development across India.